Amy Ellingson, MD
Allergy & Immunology · Willmar, MNNPI 1417032160
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 8.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $419, 2.2 times the $186 reported in 2019.
Across 98 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$126
- Takeda Pharmaceuticals U.S.A., Inc.$125
- Amgen$118
- CSL Behring$116
- Pharming Healthcare, Inc.$87
- Grifols USA, LLC$84
- plus $886 from 24 others
What the payments were for
- Food & beverage$1,48596%
- Education$564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 7 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $125 |
| Amgen | 7 | $118 |
| CSL Behring | 8 | $116 |
| Pharming Healthcare, Inc. | 6 | $87 |
| Grifols USA, LLC | 6 | $84 |
| GSK | 6 | $84 |
| Ionis Pharmaceuticals, Inc. | 3 | $68 |
| Sanofi | 4 | $65 |
| AstraZeneca | 4 | $63 |
| Genentech USA, Inc. | 3 | $54 |
| Optinose US, Inc. | 4 | $52 |
| Verona Pharma, Inc. | 3 | $50 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $41 |
| Boehringer Ingelheim | 3 | $40 |
| Cycle Pharmaceuticals Inc | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Mylan Specialty L.p. | 3 | $37 |
| Incyte Corporation | 2 | $37 |
| LEO Pharma Inc. | 2 | $32 |
| Phadia US Inc. | 2 | $32 |
| Shire North American Group Inc | 2 | $29 |
| Viatris Specialty LLC | 1 | $19 |
| Bio Products Laboratory USA, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $17 |
| Novartis | 1 | $16 |
| Octapharma USA, Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Philips North America LLC | 1 | $12 |
How this compares
$1,541 in reported general payments places this provider in the 70th percentile of 57 allergy & immunology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $47,480 |
| Zileuton ErZileuton | 12 | $15,329 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $14,956 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $13,668 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $12,639 |
| QnaslBeclomethasone Dipropionate | 12 | $8,639 |
| DuleraMometasone/Formoterol | 15 | $7,121 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $6,511 |
| Fluticasone Propionate HfaFluticasone Propionate | 18 | $5,515 |
| Arnuity ElliptaFluticasone Furoate | 14 | $4,900 |
| Azelastine Hcl | 123 | $2,298 |
| Fluticasone Propionate | 100 | $1,534 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,144 |
| Montelukast Sodium | 85 | $1,126 |
| Mometasone Furoate | 11 | $1,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $84 | $67,335105 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl | $38 | $8,63912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 57 allergy & immunology providers in Minnesota.
Other allergy & immunology in Willmar
- Nicole ChaseSaint Paul$1.8M
- Jason RaaschPlymouth$153K
- Thanai PongdeeRochester$58K
- Elina JerschowRochester$45K
- Nancy OttMinneapolis$23K
- David LoweRochester$18K
- Srinivasan RamanujaMankato$18K
- Douglas McMahonMaplewood$18K
- Niladri AichbhaumikSaint Paul$15K
- Dayne VoelkerRochester$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.